Who is sponsoring NCT06799026?

NCT06799026 is sponsored by David Avigan.

What condition does NCT06799026 study?

NCT06799026 studies Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma.

What drugs are being tested in NCT06799026?

Interventions: Elranatamab, GM-CSF, DC/MM Fusion Vaccine.

What is the status of NCT06799026?

NCT06799026 is currently RECRUITING.

Last reviewed 2025-09-02 · How we verify

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

NCT06799026 PHASE1 RECRUITING

This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory Multiple Myeloma (MM). The names of the study drugs and vaccine involved in this study are: * DC/MM fusion vaccine (a personalized cancer vaccine in which harvested participant tumor cells are fused with harvested participant dendritic blood cells) * Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (a type of growth factor) * Elranatamab (a type of T-cell engager antibody)

Details

Lead sponsor	David Avigan
Phase	PHASE1
Status	RECRUITING
Enrolment	25
Start date	Fri Jan 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Sep 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Multiple Myeloma
Relapse Multiple Myeloma
Refractory Multiple Myeloma

Interventions

Elranatamab
GM-CSF
DC/MM Fusion Vaccine

Countries

United States